Company intelligence / Profile preview

Ossianix

Stevenage, Hertfordshire, United Kingdomossianix.co.uk ↗
Ownership
Private
Employees
~50
Development stage
Preclinical
01

Overview

Developing biological drugs from shark single domain antibodies with a focus on blood-brain barrier penetrant biologics. Their TXP1 Brain Shuttle enhances delivery of therapeutic payloads to the brain by >30-fold.

Therapeutic areas
Metabolic DisordersEndocrinologyOncologyNeurologyInfectious Diseases
Modalities
Single domain antibodiesBispecific antibodiesTrispecific antibodiesRecombinant polypeptides
Industry
Biotech
02

Drug pipeline

10 assets

TXP1-TREM2

Preclinical

9 more assets in the full pipeline.

03

Partnerships

Lundbeck PharmaceuticalsNovo NordiskThe Michael J. Fox Foundation

Beyond the preview

Go deeper on Ossianix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ossianix.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call